Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.
暂无分享,去创建一个
Parag Aggarwal | Scott E. McNeil | Marina A. Dobrovolskaia | J. B. Hall | M. Dobrovolskaia | S. McNeil | Jennifer B Hall | Parag Aggarwal | Jennifer B. Hall
[1] E. W. Meijer,et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[2] Sabina Passamonti,et al. Hemolytic effects of water-soluble fullerene derivatives. , 2004, Journal of medicinal chemistry.
[3] J. Benoit,et al. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. , 2006, Journal of biomedical materials research. Part A.
[4] M. Morandi,et al. Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.
[5] M. Frank,et al. The role of complement in inflammation and phagocytosis. , 1991, Immunology today.
[6] N. K. Jain,et al. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro , 2007, Journal of drug targeting.
[7] P. Buehler,et al. Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor. , 2007, Antioxidants & redox signaling.
[8] J. B. Hall,et al. Characterization of nanoparticles for therapeutics. , 2007, Nanomedicine.
[9] T. Dutta,et al. Investigations on the toxicological profile of functionalized fifth‐generation poly(propylene imine) dendrimer , 2006, The Journal of pharmacy and pharmacology.
[10] Takuro Niidome,et al. PEG-modified gold nanorods with a stealth character for in vivo applications. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[11] M. Bryszewska,et al. Influence of PAMAM dendrimers on human red blood cells. , 2004, Bioelectrochemistry.
[12] Dipak K. Sarker,et al. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.
[13] Sara Linse,et al. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. , 2007, Advances in colloid and interface science.
[14] H. El-Shall,et al. Interaction of PLGA nanoparticles with human blood constituents. , 2005, Colloids and surfaces. B, Biointerfaces.
[15] Hong-Zhuan Chen,et al. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[16] F M Muggia,et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[18] H. Movat,et al. PLATELET PHAGOCYTOSIS AND AGGREGATION , 1965, The Journal of cell biology.
[19] J. Alonso-Lebrero,et al. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. , 2006, Journal of nanoscience and nanotechnology.
[20] S. Davis,et al. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[21] A. D. De Groot,et al. Novel function of complement C3d as an autologous helper T‐cell target , 2008, Immunology and cell biology.
[22] R. Müller,et al. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. , 1996, Journal of drug targeting.
[23] J. Oh,et al. Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles , 2005, Pharmaceutical Research.
[24] J. Cohen,et al. Apoptosis: the physiologic pathway of cell death. , 1993, Hospital practice.
[25] R. Müller,et al. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[26] J. Nah,et al. Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. , 2006, Journal of nanoscience and nanotechnology.
[27] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[28] Lawrence Tamarkin,et al. Colloidal Gold: A Novel Nanoparticle Vector for Tumor Directed Drug Delivery , 2004, Drug delivery.
[29] L. Yahia,et al. Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. , 2004, Biomaterials.
[30] R. Mumper,et al. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. , 2002, International journal of pharmaceutics.
[31] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[32] C. Vauthier,et al. Complement Activation by Core–Shell Poly(isobutylcyanoacrylate)–Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide , 2006, Pharmaceutical Research.
[33] M. Alonso,et al. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[34] A. Schroit,et al. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. , 1985, The Journal of biological chemistry.
[35] Mark E. Davis,et al. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. , 2007, Bioconjugate chemistry.
[36] R. Eritja,et al. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. , 2007, Chemistry.
[37] T Sakthivel,et al. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. , 2000, International journal of pharmaceutics.
[38] N. M. Khazenzon,et al. Nanoconjugate based on polymalic acid for tumor targeting. , 2008, Chemico-biological interactions.
[39] K. Higaki,et al. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.
[40] A. Zahr,et al. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). , 2006, Langmuir : the ACS journal of surfaces and colloids.